A carregar...
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
Epidermal growth factor receptor (EGFR) mutations (EGFRm(+)) occur in 10–35% of non-small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs are standard treatments for NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R point muta...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5610029/ https://ncbi.nlm.nih.gov/pubmed/28969097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19925 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|